- Now offering Cytiva Diagnostic Services, new diagnostic test
development and support service virtually or at new lab, for
point-of-care diagnostic developers to increase speed to market of
new tests.
- Supply chain enhancements include increasing inventory,
investing in plants and expanding number of partner
organizations.
AMERSHAM, United Kingdom,
Oct. 27, 2020 /PRNewswire/
-- Cytiva launches new services for diagnostic developers and
will establish new labs to meet the future needs of the industry.
Cytiva Diagnostic Services will help developers bring point-of-care
diagnostic tests to market quicker through infrastructure,
expertise and consultation for point of care immunoassay
development. A multi-million dollar investment will be used partly
to expand chemistry labs in Cardiff,
Wales as well as establishing design labs in Germany and China.
Cytiva has had a critical role working with diagnostic
developers during the COVID-19 pandemic. In total, over 50 million
people have been PCR tested using components or services from
Cytiva. Diagnostic components, such as nitrocellulose membranes,
are used in 18 immunoassay-based COVID-19 tests available
today.
Investment in its molecular diagnostic component lab in
Wales means more work with
companies such as genedrive, a molecular diagnostics company.
David Budd, CEO genedrive says, "Our
R&D teams worked effectively together in combining their
expertise, experience, and technologies to deliver innovative PCR
Kits based on Cytiva's 'Ready-to-Go' formulations. The speed at
which we were able to move together was facilitated by many
previous years of cooperative working."
The new services will follow the same collaborative approach as
Cytiva's work with Avacta. The companies are co-developing a rapid
antigen test strip for COVID-19 to provide a result in minutes
using patient saliva.
Alastair Smith, CEO of Avacta,
comments: "Cytiva has been a key partner in developing a rapid
coronavirus antigen test and we continue to work closely with them,
and our manufacturing partners, to finalise the test in a format
suitable for massively scaled-up manufacturing processes to meet
the anticipated demand."
The new services will include training, test optimization
expertise and contract development and can be hosted virtually or
in person at Cytiva's new lab in Dassel, Germany. Another lab for diagnostics
development work is being planned for China in 2021. These projects form part of
Cytiva's 500 million USD investment
over five years to expand manufacturing capacity.
Emmanuel Abate, Vice President,
Genomics and Cellular Research at Cytiva, says: "We have seen a lot
of new companies entering the field this year to address the
challenges of the pandemic. As a diagnostic component provider with
over 30 years' experience, we have a key role supporting the
industry through the next series of challenges with our
manufacturing and design expertise."
Join Cytiva's Diagnostics Virtual Summit
On
Oct 28 Cytiva is hosting a
thought-provoking and interactive virtual summit showcasing
recently launched technologies, products and solutions supporting
the development of diagnostics. Register here for the live event or
access the playback (available for 12 months).
About Cytiva
Cytiva is a global life sciences leader
with more than 7,000 associates across 40 countries dedicated to
advancing and accelerating therapeutics. As a trusted partner to
customers that range in scale and scope, Cytiva brings speed,
efficiency and capacity to research and manufacturing workflows,
enabling the development, manufacture and delivery of
transformative medicines to patients.